Randomized Study Comparing Vildagliptin vs Glibenclamide on Glucose Variability and Endothelial Function in Patients with Type 2 Diabetes Mellitus and Hypertension

References

• Lennon RP, Claussen KA, Kuersteiner KA. State of the heart: an overview of the disease burden of cardiovascular disease from an epidemiologic perspective. Prim Care. 2018;45(1):1–15. doi:10.1016/j.pop.2017.11.001
   PubMed Web of Science ®Google Scholar
• Smulyan H, Lieber A, Safar ME. Hypertension, diabetes type II, and their association: role of arterial stiffness. Am J Hypertens. 2016;29(1):5–13. doi:10.1093/ajh/hpv107
   PubMed Web of Science ®Google Scholar
• Kibel A, Selthofer-Relatic K, Drenjancevic I, et al. Coronary microvascular dysfunction in diabetes mellitus. J Int Med Res. 2017;45(6):1901–1929. doi:10.1177/0300060516675504
   PubMed Web of Science ®Google Scholar
• Shi Y, Vanhoutte PM. Macro- and microvascular endothelial dysfunction in diabetes. J Diabetes. 2017;9(5):434–449. doi:10.1111/1753-0407.12521
   PubMed Web of Science ®Google Scholar
• Jangam SR, Hayter G, Dunn TC. Individuals with type 1 and type 2 diabetes mellitus trade increased hyperglycemia for decreased hypoglycemia when glycemic variability is not improved. Diabetes Ther. 2018;9(1):395–402. doi:10.1007/s13300-017-0340-x
   PubMedGoogle Scholar
• Luo J, Qu Y, Zhang Q, Chang AM, Jacober SJ. Relationship of glucose variability with glycated hemoglobin and daily mean glucose: a post hoc analysis of data from 5 Phase 3 studies. J Diabetes Sci Technol. 2018;12(2):325–332. doi:10.1177/1932296817736315
   PubMedGoogle Scholar
• Nusca A, Tuccinardi D, Albano M, et al. Glycemic variability in the development of cardiovascular complications in diabetes. Diabetes Metab Res Rev. 2018;34(8):e3047. doi:10.1002/dmrr.3047
   PubMedGoogle Scholar
• Gómez AM, Muñoz OM, Marin A, et al. Different indexes of glycemic variability as identifiers of patients with risk of hypoglycemia in type 2 diabetes mellitus. J Diabetes Sci Technol. 2018;12(5):1007–1015. doi:10.1177/1932296818758105
   PubMedGoogle Scholar
• Ohara M, Nagaike H, Goto S, et al. Improvements of ambient hyperglycemia and glycemic variability are associated with reduction in oxidative stress for patients with type 2 diabetes. Diabetes Res Clin Pract. 2018;139:253–261. doi:10.1016/j.diabres.2018.02.017
   PubMedGoogle Scholar
• Vianna AGD, Lacerda CS, Pechmann LM, Polesel MG, Marino EC, Faria-Neto JR. A randomized controlled trial to compare the effects of sulphonylurea gliclazide MR (modified release) and the DPP-4 inhibitor vildagliptin on glycemic variability and control measured by continuous glucose monitoring (CGM) in Brazilian women with type 2 diabetes. Diabetes Res Clin Pract. 2018;139:357–365. doi:10.1016/j.diabres.2018.03.035
   PubMedGoogle Scholar
• Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 inhibitors. Circ Res. 2018;122(10):1439–1459. doi:10.1161/CIRCRESAHA.117.311588
   PubMed Web of Science ®Google Scholar
• Xie W, Song X, Liu Z. Impact of dipeptidyl-peptidase 4 inhibitors on cardiovascular diseases. Vascul Pharmacol. 2018;109:17–26. doi:10.1016/j.vph.2018.05.010
   PubMed Web of Science ®Google Scholar
• Cosenso-Martin LN, Giollo-Júnior LT, Fernandes LAB, et al. Effect of vildagliptin versus glibenclamide on endothelial function and arterial stiffness in patients with type 2 diabetes and hypertension: a randomized controlled trial. Acta Diabetol. 2018;55(12):1237–1245. doi:10.1007/s00592-018-1204-1
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, E B, et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326. doi:10.1056/NEJMoa1307684
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al.; EXAMINE Investigators. Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. N Engl J Med. 2013;369(14):1327–1335. doi:10.1056/NEJMoa1305889
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al.; TECOS Study Group. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242. doi:10.1056/NEJMoa1501352
   PubMed Web of Science ®Google Scholar
• Cosenso-Martin LN, Giollo-Junior LT, Martinelli DD, et al. Twelve-week randomized study to compare the effect of vildagliptin vs. glibenclamide both added-on to metformin on endothelium function in patients with type 2 diabetes and hypertension. Diabetol Metab Syndr. 2015;7:70. doi:10.1186/s13098-015-0062-z
   PubMedGoogle Scholar
• Pimazoni-Netto A, Rodbard D, Zanella MT; Diabetes Education and Control Group. Rapid improvement of glycemic control in type 2 diabetes using weekly intensive multifactorial interventions: structured glucose monitoring, patient education, and adjustment of therapy - a randomized controlled trial. Diabetes Technol Ther. 2011;13(10):997–1004. doi:10.1089/dia.2011.0054
   PubMedGoogle Scholar
• Brazilian Diabetes Society Guidelines: 2019–2020 [homepage on the Internet]. Sao Paulo: Clannad. Sociedade Brasileira de Diabetes; 2019. Available from: https://www.diabetes.org.br/profissionais/images/DIRETRIZES-COMPLETA-2019-2020.pdf. Accessed August 5, 2020.
   Google Scholar
• Fofonka A, Bock PM, Casali KR, et al. Impact of treatment with glibenclamide or vildagliptin on glucose variability after aerobic exercise in type 2 diabetes: a randomized controlled trial. Diabetes Res Clin Pract. 2018;143:184–193. doi:10.1016/j.diabres.2018.07.007
   PubMedGoogle Scholar
• Kim G, Oh S, Jin SM, et al. Safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus. Expert Opin Pharmacother. 2017;18(12):1179–1186. doi:10.1080/14656566.2017.1353080
   PubMed Web of Science ®Google Scholar
• Nagaike H, Ohara M, Kohata Y, et al. Effect of dulaglutide versus liraglutide on glucose variability, oxidative stress, and endothelial function in type 2 diabetes: a prospective study. Diabetes Ther. 2019;10(1):215–228. doi:10.1007/s13300-018-0560-8
   PubMedGoogle Scholar
• van Poppel PC, Netea MG, Smits P, Tack CJ. Vildagliptin improves endothelium- dependent vasodilatation in type 2 diabetes. Diabetes Care. 2011;34(9):2072–2077. doi:10.2337/dc10-2421
   PubMed Web of Science ®Google Scholar
• Bonetti PO, Pumper GM, Higano ST, Jr DR H, Kuvin JT, Lerman A. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. 2004;44(11):2137–2141. doi:10.1016/j.jacc.2004.08.062
   PubMed Web of Science ®Google Scholar
• Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E. Effect of glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes – a randomized, single-blinded, cross-over pilot study. Cardiovasc Diabetol. 2015;14:41. doi:10.1186/s12933-015-0206-3
   PubMed Web of Science ®Google Scholar
• Ceriello A, Novials A, Canivell S, et al. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes. Diabetes Care. 2014;37(7):1938–1943. doi:10.2337/dc13-2618
   PubMed Web of Science ®Google Scholar
• Pujadas G, De Nigris V, Prattichizzo F, La Sala L, Testa R, Ceriello A. The dipeptidyl peptidase-4 (DPP-4) inhibitor teneligliptin functions as antioxidant on human endothelial cells exposed to chronic hyperglycemia and metabolic high-glucose memory. Endocrine. 2017;56(3):509–520. doi:10.1007/s12020-016-1052-0
   PubMedGoogle Scholar
• Woodman OL, Ortega JM, Hart JL, Klein T, Potocnik S. Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride. Diabetes Metab Syndr Obes. 2019;12:1449–1458. doi:10.2147/DMSO.S215086
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al.; CARMELINA Investigators. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79. doi:10.1001/jama.2018.18269
   PubMed Web of Science ®Google Scholar
• Cardoso CRL, Leite NC, Moram CBM, Salles GM. Long-term visit-to-visit glycemic variability as predictor of micro- and macrovascular complications in patients with type 2 diabetes: the Rio de Janeiro type 2 diabetes cohort study. Cardiovasc Diabetol. 2018;17(1):33. doi:10.1186/s12933-018-0677-0
   PubMedGoogle Scholar
• Gorst C, Kwok CS, Aslam S, et al. Long-term glycemic variability and risk of adverse outcomes: a systematic review and meta-analysis. Diabetes Care. 2015;38(12):2354–2369. doi:10.2337/dc15-1188
   PubMed Web of Science ®Google Scholar
• Jun JE, Lee SE, Lee YB, et al. Continuous glucose monitoring defined glucose variability is associated with cardiovascular autonomic neuropathy in type 1 diabetes. Diabetes Metab Res Rev. 2019;35(2):e3092. doi:10.1002/dmrr.3092
   PubMedGoogle Scholar
• Wen J, Hu F, Yang Q. Comparison of hemoglobin alc, glycated albumin and fasting plasma glucose for prediction of arterial stiffness in chinese adults. Diabetes Metab Syndr Obes. 2020;13:65–70. doi:10.2147/DMSO.S230435
   PubMedGoogle Scholar
• Alam MA, Chowdhury MRH, Jain P, Sagor MAT, Reza HM. DPP-4 inhibitor sitagliptin prevents inflammation and oxidative stress of heart and kidney in two kidney and one clip (2K1C) rats. Diabetol Metab Syndr. 2015;7:107. doi:10.1186/s13098-015-0095-3
   PubMed Web of Science ®Google Scholar
• Borkowska A, Szymanska-Garbacz E, Kwiecinska E, Ignaczak A, Czupryniak L. Glucose variability and glycated hemoglobin HbA1c in type 1 and type 2 diabetes. Clin Diabetol. 2017;6(2):48–56. doi:10.5603/DK.2017.0009
   Google Scholar